@entity13332 for treatment of @entity308 and comorbidities in XXXX .

@entity1 @entity308 @entity353 @entity303 @entity13332 @entity4270 @entity148 @entity195 @entity2414 @entity25 @entity22
BACKGROUND: @entity308 in @entity1 with @entity195 is a treatable cause of functional decline, caregiver burden, and mortality. It is often associated with severe @entity353 , @entity22 , and @entity148 . These symptoms independently and collaboratively further worsen the prognosis of these vulnerable patients. An antidepressant medication with good adverse effect profile and salutary effects on these comorbid symptoms may be of significant therapeutic value in these @entity1 . OBJECTIVE: To describe the role of @entity13332 in the treatment of depressed @entity195 @entity1 with comorbid @entity353 , @entity22 , and @entity148 . CASE SUMMARY: Three @entity1 with @entity303 and @entity308 complicated by @entity353 , @entity22 , and @entity148 were treated with @entity13332 at an outpatient @entity2414 clinic of a university hospital. DISCUSSION: Despite the persistence of @entity2414 , the @entity1 experienced a prompt and sustained response to @entity13332 . There was a complete remission of poor appetite, @entity353 , @entity25 , and @entity148 . Other @entity308 symptoms, including sad mood, @entity4270 , and energy level, were also substantially improved. CONCLUSIONS: The clinical response of our @entity1 underscores the usefulness of @entity13332 in the treatment of the comorbid symptoms of @entity353 , @entity22 , and @entity148 . The effectiveness of @entity13332 in depressed @entity195 patents may be a reflection of its enhancement of brain serotonergic and noradrenergic neurotransmission. The usefulness of @entity13332 in depressed @entity195 @entity1 merits further study in a large randomized, controlled, clinically comparative trial.
